Daraxonrasib demonstrates encouraging disease cont..

25 w

Daraxonrasib demonstrates encouraging disease control and manageable side effects in an early trial of RAS-driven pancreatic cancer, signaling potential as researchers pursue larger studies.

news.spreely.com

Daraxonrasib Shrinks RAS Mutant Pancreatic Tumors, Early Trial

Researchers report that daraxonrasib, an oral drug designed to block RAS-driven cancer signals, has shown encouraging results in an early clinical trial for advanced pancreatic cancer, producing notable disease control and manageable side effects while remaining investigational pending larger trials. Daraxonrasib is a daily pill meant to shut down multiple cancer signals tied to the...

Comment

25 w

Daraxonrasib Shrinks RAS Mutant Pancreatic Tumors, Early Trial

Language